Percutaneous Ethibloc injection in the treatment of primary aneurysmal bone cysts.
The effects of percutaneous Ethibloc (Ethicon/Johnson & Johnson, St-Stevens-Woluwe, Belgium) injection into primary aneurysmal bone cysts were analysed. Two patients with a venous drainage after injection of a medium contrast were excluded. Twelve patients underwent at least one percutaneous injection of Ethibloc. The average follow-up period was 5.1 years. At final follow-up, six patients had complete healing of the cyst, three had partial healing and three, who had no response, were treated by curettage and bone grafting. Complete healing was observed for all the aggressive lesions. No major complications were noted. Ethibloc injection may be performed as a primary treatment of aneurysmal bone cysts if the technique is followed with precision.
de Gauzy
Jérôme Sales
JS
Department of Orthopaedic Pediatric Surgery, CHU, Toulouse, France.
Abid
Abdelazis
A
Accadbled
Franck
F
Knorr
Gorka
G
Darodes
Philippe
P
Cahuzac
Jean Philippe
JP
D000082:Acetaminophen / Q000627:therapeutic use; D000293:Adolescent; D018712:Analgesics, Non-Narcotic / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D017824:Bone Cysts, Aneurysmal / Q000188:drug therapy*; D002648:Child; D002675:Child, Preschool; D003973:Diatrizoate / Q000627:therapeutic use*; D004338:Drug Combinations; D005227:Fatty Acids / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015552:Injections, Intralesional; D008297:Male; D011409:Propylene Glycols / Q000627:therapeutic use*; D012597:Sclerosing Solutions / Q000627:therapeutic use*; D016896:Treatment Outcome; D015028:Zein / Q000627:therapeutic use*
D018712:Analgesics, Non-Narcotic; D000894:Anti-Inflammatory Agents, Non-Steroidal; D004338:Drug Combinations; D005227:Fatty Acids; D011409:Propylene Glycols; D012597:Sclerosing Solutions; D003973:Diatrizoate; D000082:Acetaminophen; D015028:Zein; C020481:alcoholic prolamine solution